Investor Firms Urge ImmunityBio Shareholders to Seek Lead Role in Anktiva-Linked Securities Suit

Overview

• Two shareholder law firms, Schall and DJS, issued reminders inviting ImmunityBio investors to join a securities class action and to seek a lead-plaintiff role before the May 26, 2026 deadline.
• The complaints say ImmunityBio made false and misleading statements by overstating the capabilities of its cancer drug Anktiva in public promotions.
• The proposed class period covers purchases made between January 19 and March 24, 2026.
• The filings invoke Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5.
• The class has not been certified yet, so investors are not represented unless they contact counsel, and becoming lead plaintiff is not required to share in any recovery.